
Q2 & 1H 2026 - Undisclosed
Strong organic EBITA growth supported by top-line, and increased resilience through repair, maintenance, and aftermarket services
Sharing in-depth reports on high-quality compounders | Unpacking financial analysis topics
Live Last read · last published · next check

Strong organic EBITA growth supported by top-line, and increased resilience through repair, maintenance, and aftermarket services

Thoughts on why quarterly headline numbers drive more volatility

Establishing a small position; <300 million EUR market cap, high-teens percent growth, net cash, and trading at 10x FY28 NOPAT (EV-based)

Margin pressure due to incoming acquisitions and timing, 3.5% organic maintenance revenue growth ex. Altera

Exceptional growth with 23% EBITA growth, despite FX headwinds

Small M&A still sluggish, and lowest IRR within the CSI family

>70% growth on a two-year stack in North America, fwd. annualized returns still above 18%

The expected EBITA rebound in Q2 - record capital deployment should drive close to 30% EBITA growth in FY27

Margin progression's stalled, including and excluding US home care challenges

Massive buybacks of 1.5 billion USD in Q2 - modest guidance raise was in the cards

Selling out of a smaller-sized position we trimmed well; buying more of a promising serial acquirer